List of Excipients in Branded Drug MYSOLINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	MYSOLINE	primidone	66490-690	CELLULOSE, MICROCRYSTALLINE
Bausch Health US LLC	MYSOLINE	primidone	66490-690	LACTOSE MONOHYDRATE
Bausch Health US LLC	MYSOLINE	primidone	66490-690	MAGNESIUM STEARATE

# Mysoline Excipient Strategy and Commercial Opportunities for Primidone Tablets

Last updated: September 2, 2026

Mysoline is an immediate-release oral primidone product used for generalized, psychomotor, and focal epileptic seizures. Its commercial protection is weak because primidone is an established generic active ingredient with no meaningful remaining composition-of-matter exclusivity. The strongest opportunities are differentiated dosage forms, pediatric and geriatric delivery, adherence-focused packaging, and excipient systems that improve dissolution, taste, swallowability, and dose flexibility.

The commercial case is more favorable for a reformulated primidone product than for another conventional tablet. A standard tablet would compete primarily on price against generic primidone products.

What is Mysoline and which excipients does it contain?

Mysoline is the brand name for primidone, an anticonvulsant that is metabolized partly to phenobarbital and phenylethylmalonamide. The US product is supplied as 50 mg and 250 mg immediate-release tablets.[1]

The US labeling identifies the core inactive ingredients as:

Product	Strength	Dosage form	Reported inactive ingredients
Mysoline	50 mg	Immediate-release tablet	Corn starch, povidone, magnesium stearate
Mysoline	250 mg	Immediate-release tablet	Corn starch, povidone, magnesium stearate

The formulation is conventional. Corn starch functions primarily as a diluent and disintegrant. Povidone is a binder. Magnesium stearate is a lubricant. The label does not identify a modified-release matrix, taste-masking system, enteric coating, lipid carrier, or specialized delivery technology.[1]

The basic excipient system creates a low-cost manufacturing benchmark. Any new product must produce a clinically relevant or commercially valuable improvement rather than simply substitute one conventional filler for another.

What formulation opportunities exist for Mysoline?

The most attractive opportunities involve dosage forms that solve practical limitations of standard primidone tablets.

Pediatric oral liquid

A ready-to-use oral suspension or solution could address patients who cannot swallow tablets and support weight-based dosing. Primidone is used in pediatric seizure management, although the marketed Mysoline tablet presentation is not optimized for infants or young children.[1]

A liquid product would require control of:

• Chemical stability in aqueous media
• Uniformity of dispersed primidone
• Sedimentation and redispersibility
• Taste and mouthfeel
• Microbial preservation
• Dose accuracy at low volumes
• Compatibility with oral syringes and feeding devices

Primidone has a bitter pharmaceutical taste. Taste masking could use polymeric coating, ion-pairing, complexation, lipid-based barriers, or sweetener-flavor systems. A simple syrup formulation may be inadequate if it produces poor adherence or dose refusal.

The regulatory route could be an ANDA if the product satisfies applicable bioequivalence and pharmaceutical-equivalence requirements. A more differentiated formulation may be eligible for a 505(b)(2) application if it relies on a new dosage form, route, or clinical advantage supported by bridging studies.[2]

Orally disintegrating tablet

An orally disintegrating tablet could improve administration for elderly patients, patients with dysphagia, and patients experiencing acute postictal impairment. Key development issues include:

• Fast disintegration without excessive friability
• Adequate mechanical strength
• Taste masking
• Low-dose content uniformity
• Packaging protection against moisture
• Compatibility with tablet splitting requirements

Potential excipient systems include mannitol for mouthfeel, crospovidone or croscarmellose sodium for disintegration, and a coated or complexed primidone fraction for taste control.

An orally disintegrating tablet would have stronger commercial differentiation than a new standard tablet, but its value depends on whether prescribers and payers recognize a meaningful adherence or administration benefit.

Scored and low-dose titration tablets

Primidone therapy often requires gradual dose escalation because of sedation, dizziness, ataxia, and other central nervous system effects. The 50 mg Mysoline tablet supports lower-dose titration, but a broader strength portfolio could improve dosing precision.

Potential products include:

• 25 mg tablets
• 50 mg tablets with improved score uniformity
• 125 mg intermediate-strength tablets
• Unit-dose titration packs
• Calendar packaging with escalating daily doses

The main opportunity is not a new excipient but a dosing architecture. A 25 mg product could reduce tablet-splitting variability and support initiation in sensitive patients. Any tablet-splitting claim would require validated dose uniformity and appropriate scoring data.

Sprinkle capsule or multiparticulate formulation

A sprinkle capsule containing coated primidone granules could be opened and administered with soft food. This format could help patients with swallowing difficulty while avoiding the stability and preservation challenges of a liquid.

The formulation would need:

• Uniform primidone loading across particles
• Protection from moisture
• Limited drug release before administration
• Acceptable taste after mixing with food
• Demonstrated bioavailability against the reference product

Multiparticulates also create a potential platform for modified release. A controlled-release product could reduce peak-related adverse effects and simplify dosing, but it would require clinical and pharmacokinetic evidence because primidone’s metabolites contribute to pharmacologic activity.

Which excipient technologies are most commercially attractive?

Strategy	Primary patient problem	Commercial attractiveness	Main technical risk
Oral suspension	Dysphagia, pediatric dosing	High	Stability, taste, preservation
Orally disintegrating tablet	Swallowing difficulty, adherence	Moderate to high	Taste masking and friability
Sprinkle capsule	Administration with food	Moderate	Food effect and multiparticulate uniformity
25 mg titration tablet	Dose escalation	Moderate	Small market and generic substitution
Modified-release tablet	Peak-related adverse effects, adherence	High if clinically successful	PK, metabolite exposure, clinical evidence
Chewable tablet	Pediatric administration	Moderate	Bitterness and patient acceptance
Standard reformulated tablet	Manufacturing or supply benefit	Low	Price competition

A sustained-release product has the largest potential value but also the highest development risk. A liquid, orally disintegrating tablet, or sprinkle product offers a more direct path to patient differentiation.

What patents protect Mysoline and primidone formulations?

The original active-ingredient protection for primidone has expired. Mysoline is an old small-molecule product, and conventional primidone tablets do not have the type of current composition-of-matter protection associated with recently launched branded drugs.

The principal patent opportunity is therefore a new formulation patent, not a patent on primidone itself. Potential claim categories include:

• Specific polymeric taste-masking systems
• Stable aqueous primidone compositions
• Multiparticulate dosage forms
• Modified-release matrices
• Defined particle-size distributions
• Low-dose titration regimens linked to a particular dosage form
• Packaging and moisture-control systems
• Combination products involving primidone and another anticonvulsant

A formulation patent must contain a defensible technical distinction. Claims limited to routine substitutions among corn starch, lactose, povidone, crospovidone, or magnesium stearate would face substantial obviousness risk under US patent law.

A stronger estate would combine composition claims, manufacturing-process claims, dosage-form claims, and clinically supported method-of-use claims. Method-of-use protection could address a defined patient population or dosing schedule, but broad seizure-treatment claims would likely face prior-art challenges because primidone’s use in epilepsy is longstanding.

When does Mysoline lose exclusivity?

Mysoline has already lost practical US market exclusivity. Primidone is available from multiple generic manufacturers, and the FDA-approved product category is mature.[3]

Exclusivity component	Mysoline status
New chemical entity exclusivity	Expired
Composition-of-matter patent	Expired or no longer commercially relevant
Current branded tablet exclusivity	No meaningful barrier to generic competition
Orange Book patent barrier	No material barrier expected for conventional primidone tablets
Biosimilar exclusivity	Not applicable
Generic competition	Established

Because Mysoline is a small-molecule drug, biosimilar rules do not apply. Competitive entry occurs through ANDAs rather than abbreviated biologics license applications.

What is the Orange Book status of Mysoline?

The Orange Book is relevant to any proposed generic or reformulated primidone product because it identifies approved products, therapeutic-equivalence evaluations, and certain listed patents and exclusivities.[3]

For a conventional primidone tablet, the commercial environment is consistent with an off-patent multisource product. A new formulation sponsor should conduct a product-specific Orange Book review before filing because regulatory status can change through new approvals, patent listings, or changes in reference-product designation.

A 505(b)(2) product may have a different exclusivity profile from a standard ANDA. If FDA approves a clinically distinct new formulation, the sponsor could seek three years of marketing exclusivity for certain new clinical investigations, although that exclusivity would not necessarily block all generic primidone products.[2]

What Paragraph IV challenges and generic launch risks exist?

Paragraph IV litigation risk for the current Mysoline tablet is limited because generic primidone products are already marketed. The more relevant risk applies to a new branded formulation.

A sponsor pursuing an improved primidone product could face:

• ANDA filings against listed formulation patents
• Paragraph IV notices challenging obviousness
• Arguments that the formulation lacks unexpected results
• Design-around products using different polymers or release mechanisms
• Substitution pressure from low-cost immediate-release tablets
• Formulary resistance to premium pricing

A settlement agreement involving a new primidone formulation would need careful antitrust review. A conventional authorized-generic strategy could reduce litigation exposure but would also limit the branded product’s price premium.

How strong is the patent estate for a new Mysoline formulation?

The patent estate for existing Mysoline tablets is weak. The estate for a newly developed formulation could be moderate if it is supported by reproducible performance data.

Stronger patent features

• Unexpected improvement in dissolution or stability
• Clinically meaningful reduction in peak plasma concentration
• Demonstrated reduction in sedation or early-treatment discontinuation
• Stable liquid formulation with long in-use shelf life
• Taste masking that improves pediatric acceptance
• Robust multiparticulate manufacturing process
• Narrow but commercially important patient population

Weaker patent features

• Routine excipient substitution
• Conventional tablet compression
• Generic flavor and sweetener systems
• Broad claims covering all oral primidone formulations
• Claims based only on better patient convenience without clinical support
• A new strength without demonstrated dosing or adherence benefit

The strongest commercial strategy would pair formulation patents with regulatory exclusivity, trade secrets covering manufacturing parameters, and proprietary packaging or dosing systems.

Which companies are challenging or competing with Mysoline?

The principal competitive threat comes from generic primidone manufacturers rather than a single branded challenger. Generic competition affects price, pharmacy substitution, wholesaler access, and payer coverage.

A differentiated product would compete against:

1. Generic immediate-release primidone tablets
2. Phenobarbital and other established anticonvulsants
3. Newer antiseizure medicines with broader formulations
4. Extemporaneously compounded primidone liquids
5. Alternative delivery systems for patients with dysphagia

Mysoline’s brand value is limited unless the sponsor can demonstrate supply reliability, dose flexibility, or a formulation benefit not available from generic tablets.

What licensing and commercial opportunities exist?

Licensing opportunities are strongest for companies that already have:

• Pediatric oral-liquid infrastructure
• Multiparticulate coating technology
• Orally disintegrating tablet platforms
• Modified-release expertise
• Established neurology sales channels
• Hospital and specialty-pharmacy distribution

A rights holder could pursue several models:

Commercial model	Use case	Value proposition
ANDA generic	Conventional tablet	Low development cost, low margin
505(b)(2) reformulation	Liquid, ODT, sprinkle, modified release	Potential clinical differentiation
Co-development	Specialty formulation platform	Shares development and regulatory risk
Licensing	Regional commercialization	Access to local sales and reimbursement
Authorized generic	Brand-linked generic supply	Controls manufacturing and channel economics
Pediatric extension	Liquid or low-dose product	Differentiates from adult tablets

Revenue exposure is difficult to estimate from public product labeling alone. The established generic market implies limited pricing power for standard tablets. A premium opportunity exists only if the new product solves a documented administration or tolerability problem and secures reimbursement.

What FDA regulatory status applies to a new Mysoline excipient strategy?

FDA classification depends on the product design:

• A compositionally equivalent immediate-release tablet may qualify for an ANDA.
• A new oral liquid, orally disintegrating tablet, sprinkle product, or modified-release formulation may require a 505(b)(2) pathway.
• A product with clinically important pharmacokinetic or tolerability differences may require additional clinical studies.
• A pediatric product may require age-appropriate safety, dosing, palatability, and device-use data.

Excipient selection must comply with applicable FDA inactive-ingredient expectations, compendial standards, and manufacturing controls. Novel excipients increase regulatory burden because the sponsor may need more extensive safety and quality information.[4]

The formulation should also address primidone’s metabolite profile. A modified-release system cannot be evaluated only on parent-drug exposure if metabolite exposure changes materially.

What geographic opportunities exist?

The most practical geographic strategy is regional formulation licensing.

United States

The US market offers the clearest pathway for a differentiated 505(b)(2) product, but generic price competition is intense. Orange Book strategy and Paragraph IV exposure become relevant if formulation patents are listed.

European Union

A reformulated product may use a hybrid application under Article 10(3) of Directive 2001/83/EC when the proposed product differs from the reference product in dosage form, strength, route, or other material characteristics.[5]

Emerging markets

Pediatric liquids, lower strengths, and reliable blister packaging may have greater practical value where compounded medicines are less consistently available. Regulatory requirements, local reference products, and pricing controls vary by country.

Key Takeaways

• Mysoline contains primidone and is marketed as a conventional immediate-release tablet.
• Its reported excipients are corn starch, povidone, and magnesium stearate.
• Existing Mysoline tablets have little practical exclusivity because primidone is an established generic drug.
• A new conventional tablet would face low margins and rapid generic substitution.
• The strongest excipient-led opportunities are pediatric liquids, orally disintegrating tablets, sprinkle capsules, and modified-release systems.
• Taste masking, stability, dose uniformity, and bioequivalence are the central development issues.
• A new formulation could support 505(b)(2) development and formulation-patent protection.
• Biosimilar risk does not apply because primidone is a small-molecule drug.
• The most defensible patent estate would combine formulation, process, packaging, and clinically supported method-of-use claims.

FAQs

Can Mysoline be reformulated as a liquid for children?

Yes. A primidone oral liquid is technically feasible, but the formulation must address bitterness, chemical stability, sedimentation, dose uniformity, preservation, and dosing-device compatibility.

Would a new Mysoline excipient automatically receive patent protection?

No. Excipient changes must produce a non-obvious formulation with a defensible technical effect. Routine substitutions among standard pharmaceutical excipients are vulnerable to invalidity challenges.

Is an orally disintegrating primidone tablet likely to command a premium?

It could, if it improves administration or adherence for patients with dysphagia and demonstrates adequate taste masking. Without evidence of patient or clinical benefit, payers may treat it as substitutable with generic tablets.

Could a primidone liquid qualify for FDA exclusivity?

Potentially. A clinically differentiated liquid approved through a 505(b)(2) application may qualify for certain regulatory exclusivity, subject to FDA findings and the nature of the supporting clinical investigations.

Does Mysoline have biosimilar competition?

No. Primidone is a small-molecule active ingredient. Competition occurs through generic-drug pathways, including ANDAs, rather than biosimilar applications.

References

1. DailyMed. (n.d.). Mysoline-primidone tablet: US prescribing information. National Library of Medicine.
2. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2).
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2019). Inactive ingredient database guidance and pharmaceutical quality considerations.
5. European Parliament and Council. (2001). Directive 2001/83/EC on the Community code relating to medicinal products for human use.